These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11880619)

  • 1. A cofactor approach to copper-dependent catalytic antibodies.
    Nicholas KM; Wentworth P; Harwig CW; Wentworth AD; Shafton A; Janda KD
    Proc Natl Acad Sci U S A; 2002 Mar; 99(5):2648-53. PubMed ID: 11880619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A humanized aldolase antibody for selective chemotherapy and adaptor immunotherapy.
    Rader C; Turner JM; Heine A; Shabat D; Sinha SC; Wilson IA; Lerner RA; Barbas CF
    J Mol Biol; 2003 Sep; 332(4):889-99. PubMed ID: 12972259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enantioselective aldol cyclodehydrations catalyzed by antibody 38C2.
    List B; Lerner RA; Barbas CF
    Org Lett; 1999 Jul; 1(1):59-61. PubMed ID: 10822533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple catalytic aldolase antibodies suitable for chemical programming.
    Goswami RK; Huang ZZ; Forsyth JS; Felding-Habermann B; Sinha SC
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3821-4. PubMed ID: 19428247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beta-lactam-based approach for the chemical programming of aldolase antibody 38C2.
    Gavrilyuk JI; Wuellner U; Barbas CF
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1421-4. PubMed ID: 19181522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody-catalyzed benzoin oxidation as a mechanistic probe for nucleophilic catalysis by an active site lysine.
    Sklute G; Oizerowich R; Shulman H; Keinan E
    Chemistry; 2004 May; 10(9):2159-65. PubMed ID: 15112204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Highly efficient antibody-catalyzed deuteration of carbonyl compounds.
    Shulman A; Sitry D; Shulman H; Keinan E
    Chemistry; 2002 Jan; 8(1):229-39. PubMed ID: 11822454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhancing the synthetic utility of aldolase antibody 38C2.
    Mondal K; Ramesh NG; Roy I; Gupta MN
    Bioorg Med Chem Lett; 2006 Feb; 16(4):807-10. PubMed ID: 16321532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reaction properties of catalytic antibodies encapsulated in organo substituted SiO2 sol-gel materials.
    Kato K; Saito T; Seelan S; Tomita M; Yokogawa Y
    J Biosci Bioeng; 2005 Oct; 100(4):478-80. PubMed ID: 16310742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Computational elucidation and validation of the three-dimensional structure of humanized aldolase catalytic antibody 38C2.
    Jayakody RS; Jasin Arachchige LI; Japahuge A
    J Biomol Struct Dyn; 2021 Apr; 39(7):2463-2477. PubMed ID: 32242499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evolution of aldolase antibodies in vitro: correlation of catalytic activity and reaction-based selection.
    Tanaka F; Fuller R; Shim H; Lerner RA; Barbas CF
    J Mol Biol; 2004 Jan; 335(4):1007-18. PubMed ID: 14698295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preparation of integrin alpha(v)beta3-targeting Ab 38C2 constructs.
    Sinha SC; Das S; Li LS; Lerner RA; Barbas CF
    Nat Protoc; 2007; 2(2):449-56. PubMed ID: 17406606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An efficient benchtop system for multigram-scale kinetic resolutions using aldolase antibodies.
    Turner JM; Bui T; Lerner RA; Barbas CF; List B
    Chemistry; 2000 Aug; 6(15):2772-4. PubMed ID: 10985725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule drug activity in melanoma models may be dramatically enhanced with an antibody effector.
    Popkov M; Rader C; Gonzalez B; Sinha SC; Barbas CF
    Int J Cancer; 2006 Sep; 119(5):1194-207. PubMed ID: 16570283
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Substrate-selective mechanisms in biocatalysis demonstrated with a versatile and efficient aldolase antibody.
    Shulman H; Keinan E
    Bioorg Med Chem Lett; 1999 Jul; 9(13):1745-50. PubMed ID: 10406635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of the aldolase antibody-derived chemical-antibodies targeting α5β1 integrin.
    Goswami RK; Liu Y; Liu C; Lerner RA; Sinha SC
    Mol Pharm; 2013 Feb; 10(2):538-43. PubMed ID: 23102054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient aldolase catalytic antibodies that use the enamine mechanism of natural enzymes.
    Wagner J; Lerner RA; Barbas CF
    Science; 1995 Dec; 270(5243):1797-800. PubMed ID: 8525368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune versus natural selection: antibody aldolases with enzymic rates but broader scope.
    Barbas CF; Heine A; Zhong G; Hoffmann T; Gramatikova S; Björnestedt R; List B; Anderson J; Stura EA; Wilson IA; Lerner RA
    Science; 1997 Dec; 278(5346):2085-92. PubMed ID: 9405338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic and fluorescence studies of affinity maturation in related antibodies.
    Pauyo T; Hilinski GJ; Chiu PT; Hansen DE; Choi YJ; Ratner DI; Shah-Mahoney N; Southern CA; O'Hara PB
    Mol Immunol; 2006 Mar; 43(7):812-21. PubMed ID: 16137768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aldol sensors for the rapid generation of tunable fluorescence by antibody catalysis.
    List B; Barbas CF; Lerner RA
    Proc Natl Acad Sci U S A; 1998 Dec; 95(26):15351-5. PubMed ID: 9860972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.